Patents by Inventor Dulce Soler-Ferran

Dulce Soler-Ferran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for identifying agents which modulate chemokine “MEC”-induced functions of CCR3
    Patent number: 6692922
    Abstract: The invention relates to the interaction of MEC with CCR3 and/or CCR10 and to agents (e.g., ligands, antibodies, antagonists, agonists, inhibitors, promoters) which alter said interaction. In one aspect, the invention relates to methods for detecting or identifying an agent (i.e., molecule or compound) which can modulate (inhibit, promote) the binding of MEC to CCR3 and/or CCR10. In another aspect, the invention relates to a method of treating a subject having an inflammatory condition, comprising administering to the subject an effective amount of an agent which modulates the binding of MEC to CCR3 and/or CCR10.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: February 17, 2004
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Millennium Pharmaceuticals, Inc.
    Inventors: Eugene C. Butcher, Eric J. Kunkel, Junliang Pan, Dulce Soler-Ferrán
  • Method for identifying agents which modulate chemokine "MEC"-induced functions of CCR3 and/or CCR10
    Publication number: 20020137107
    Abstract: The invention relates to the interaction of MEC with CCR3 and/or CCR10 and to agents (e.g., ligands, antibodies, antagonists, agonists, inhibitors, promoters) which alter said interaction. In one aspect, the invention relates to methods for detecting or identifying an agent (i.e., molecule or compound) which can modulate (inhibit, promote) the binding of MEC to CCR3 and/or CCR10. In another aspect, the invention relates to a method of treating a subject having an inflammatory condition, comprising administering to the subject an effective amount of an agent which modulates the binding of MEC to CCR3 and/or CCR10.
    Type: Application
    Filed: August 15, 2001
    Publication date: September 26, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Eugene C. Butcher, Eric J. Kunkel, Junliang Pan, Dulce Soler-Ferran